Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus

Pharmacotherapy

Volumn 30, Issue 10, 2010, Pages 1072-1083

  Schafer, Jason J ^a   Short, William R ^b,c   Squires, Kathleen E ^b,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Abacavir; Acquired immunodeficiency syndrome; AIDS; Cardiovascular disease; HIV; Human immunodeficiency virus; Myocardial infarction

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

BODY COMPOSITION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG EXPOSURE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; MEDICAL DECISION MAKING; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOMARKERS, PHARMACOLOGICAL; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; DIDEOXYNUCLEOSIDES; HIV; HIV INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; VIRAL LOAD;

EID: 77957672675     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.10.1072     Document Type: Review

References (36)

1. Saves M, Chene G, Ducimetiere P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003;37:292-8. (Pubitemid 36930361)
2. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Aquir Immune Defic Syndr 2003;33:506-12. (Pubitemid 36886080)
3. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004;109:1603-8. (Pubitemid 38451715)
4. Obel N, Thomson HF, Kronborg G, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population based cohort study. Clin Infect Dis 2007;44:1625-31.
5. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
6. Currier JS, Lundgren JD, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008;118:e29-35.
7. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
8. Noor MA, Seneviratne T, Aweeka FT, et al. Indinivir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002;16:F1-8.
9. Hadigen C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32:130-9. (Pubitemid 32150958)
10. D:A:D Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35.
11. Sabin CA, Worm SW, Weber R, et al, for the D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and the risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371:1417-26. (Erratum in Lancet 2008;372:292.)
12. Worm SW, Sabin CA, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010;201:318-30.
13. Lundgren JD, Neuhaus J, Babiker A, et al, for the SMART/INSIGHT and D:A:D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008;22:F17-24.
14. Cutrell A, Hernandez J, Brothers C, Yeo J, Burkle W, Spreen W. Is abacavir (ABC)-containing combination antiretroviral therapy (CART) associated with myocardial infarction (MI)? No association identified in pooled summary of 54 clinical trials [abstract WEAB0106]. Presented at the 17th international AIDS conference, Mexico City, Mexico, August 3-8, 2008.
15. Benson C, Ribaudo H, Zheng E, et al. No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTB A5001 [abstract 721]. Presented at the 16th conference on retroviruses and opportunistic infections, Montreal, Canada, February 8-11, 2009.
16. Lang S, Mary-Krause M, Cotte L, et al, for the Clinical Epidemiology Group of the French Hospital Database on HIV. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med 2010;170:1228-38.
17. Bedimo R, Westfall A, Dreschler H, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAART era [abstract MOAB202]. Presented at the 5th International AIDS Society conference on HIV pathogenesis, treatment, and prevention, Cape Town, South Africa, July 19-22, 2009.
18. Cooper DA, Bloch M, Humphries A, et al. Simplification with fixed dose tenofovir/emtricitabine or abacavir/lamivudine in adults with suppressed HIV replication: the STEAL study, a randomized, open-label, 96-week, non-inferiority trial [abstract 576]. Presented at the 16th conference on retroviruses and opportunistic infections, Montreal, Canada, February 8-11, 2009.
19. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay C. Relation between use of nucleosidic reverse transcriptase inhibitors (NRTI) and risk of myocardial infarction (MI): a nested case-control study using Quebec's public health database (QPHID) [abstract TUPEB175]. Presented at the 5th International AIDS Society conference on HIV pathogenesis, treatment, and prevention, Cape Town, South Africa, July 19-22, 2009.
20. Copenhagen HIV Programme (CHIP). The D:A:D study. Available from http://www.eurosida.org/DAD/tabid/57/Default.aspx. Accessed January 4, 2010.
21. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ countguided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96.
22. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005;111:3481-8.
23. Zakynthinos E, Pappa N. Inflammatory biomarkers in coronary artery disease. J Cardiol 2009;53:317-33.
24. De Luca A, De Gaetano Donati K, Cozi-Lepri A, et al. Abacavir treatment and biomarkers associated with cardiovascular disease (CVD) in HIV-1-infected patients on effective antiretroviral therapy [abstract CDB116]. Presented at the 5th International AIDS Society conference on HIV pathogenesis, treatment and prevention, Cape Town, South Africa, July 19-22, 2009.
25. McComsey G, Smith K, Patel P, et al. Similar reductions in markers of inflammation and endothelial activation after initiation of abacavir/lamivudine or tenofovir/emtricitabine: the HEAT study [abstract 732]. Presented at the 16th conference on retroviruses and opportunistic infections, Montreal, Canada, February 8-11, 2009.
26. Martinez E, Arranz JA, Podzamczer D, et al. No evidence for recent abacavir/lamivudine use in promoting inflammation, endothelial dysfunction, hypercoagulability, or insulin resistance in virologically suppressed HIV-infected patients: a substudy of the CICOMBO randomized clinical trial (ISRCTN6189) [abstract]. Presented at the 5th International AIDS Society conference on HIV pathogenesis, treatment and prevention, Cape Town, South Africa, July 19-22, 2009.
27. Palella F, Gange S, Elion R, et al. Inflammatory markers among abacavir and non-abacavir recipients in the womens' interagency HIV study and the multicenter AIDS cohort study [abstract 150LB]. Presented at the 16th conference on retroviruses and opportunistic infections, Montreal, Canada, February 8-11, 2009.
28. Humphries A, Amin J, Cooper D, et al. Changes in cardiovascular biomarkers with abacavir: a randomized, 96-week trial [abstract 718]. Presented at the 17th conference on retroviruses and opportunistic infections, San Francisco, CA, February 16-19, 2010.
29. Hammond E, McKinnon E, Mallal S, Nolan D. Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy. AIDS 2008;22:2540-3.
30. Satchell C, O'Connor E, Peace A, et al. Platelet hyperreactivity in HIV-1-infected patients on abacavir-containing ART [abstract 151LB]. Presented at the 16th conference on retroviruses and opportunistic infections, Montreal, Canada, February 8-11, 2009.
31. Hsue PY, Hunt PW, Wu Y, et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 2009;23:2021-7.
32. Department of Health and Human Services, Panel on Anti-retroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1, 2009:1-161. Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescent GL.pdf. Accessed April 25, 2010.
33. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. AHA/ACC scientific statement: assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 1999;34:1348-59. (Pubitemid 29500569)
34. Grundy SM, Cleeman JI, Merz NB, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004;110:227-39.
35. Law MG, Friis-Moller N, El-Sadr WM, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events. HIV Med 2006;7:218-30.
36. Friis-Moller N, Thiebaut R, Reiss P, et al. Predicting the risk of coronary heart disease (CHD) in HIV-infected patients: the D:A:D CHD risk equation [abstract 808]. Presented at the 14th conference on retroviruses and opportunistic infections, Los Angeles, CA, February 25-28, 2007.